MMP-9/Gelatinase B Degrades Immune Complexes in Systemic Lupus Erythematosus.


Journal

Frontiers in immunology
ISSN: 1664-3224
Titre abrégé: Front Immunol
Pays: Switzerland
ID NLM: 101560960

Informations de publication

Date de publication:
2019
Historique:
received: 27 09 2018
accepted: 27 02 2019
entrez: 11 4 2019
pubmed: 11 4 2019
medline: 24 9 2020
Statut: epublish

Résumé

Systemic Lupus Erythematosus (SLE) is a common and devastating autoimmune disease, characterized by a dysregulated adaptive immune response against intracellular antigens, which involves both autoreactive T and B cells. In SLE, mainly intracellular autoantigens generate autoantibodies and these assemble into immune complexes and activate the classical pathway of the complement system enhancing inflammation. Matrix metalloproteinase-9 (MMP-9) levels have been investigated in the serum of SLE patients and in control subjects. On the basis of specific studies, it has been suggested to treat SLE patients with MMP inhibitors. However, some of these inhibitors induce SLE. Analysis of LPR

Identifiants

pubmed: 30967870
doi: 10.3389/fimmu.2019.00538
pmc: PMC6440319
doi:

Substances chimiques

Apolipoprotein B-100 0
Matrix Metalloproteinase 9 EC 3.4.24.35
Mmp9 protein, mouse EC 3.4.24.35

Types de publication

Journal Article Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

538

Références

J Leukoc Biol. 1999 Sep;66(3):416-22
pubmed: 10496311
J Clin Invest. 1999 Dec;104(11):1507-15
pubmed: 10587514
J Biomed Mater Res. 2000 Jun 5;50(3):365-74
pubmed: 10737878
J Biol Chem. 2000 Oct 20;275(42):33008-13
pubmed: 10930399
J Microbiol Immunol Infect. 2000 Sep;33(3):202-4
pubmed: 11045386
FASEB J. 2002 Mar;16(3):379-89
pubmed: 11874987
FASEB J. 2003 May;17(8):887-9
pubmed: 12626433
J Autoimmun. 2003 Jun;20(4):323-31
pubmed: 12791318
Mol Pathol. 2003 Aug;56(4):244-7
pubmed: 12890748
Arthritis Rheum. 2004 Mar;50(3):858-65
pubmed: 15022328
Exp Biol Med (Maywood). 2004 Jun;229(6):538-45
pubmed: 15169973
Semin Arthritis Rheum. 2004 Oct;34(2):501-37
pubmed: 15505768
J Comp Pathol. 2005 May;132(4):313-21
pubmed: 15893989
J Clin Immunol. 2006 Jul;26(4):299-307
pubmed: 16652230
Mediators Inflamm. 2006;2006(1):17898
pubmed: 16864898
Lancet. 2007 Feb 17;369(9561):587-96
pubmed: 17307106
Ann Rheum Dis. 2008 Feb;67(2):195-205
pubmed: 17504841
Clin Biochem. 2008 Aug;41(12):955-9
pubmed: 18471998
Lupus. 2008 May;17(5):437-42
pubmed: 18490423
J Int Med Res. 2008 Jul-Aug;36(4):704-13
pubmed: 18652766
Annu Rev Immunol. 1991;9:243-69
pubmed: 1910678
Rheumatol Int. 2010 Jul;30(9):1219-26
pubmed: 19779723
Integr Biol (Camb). 2009 Jun;1(5-6):404-26
pubmed: 20023747
Crit Rev Biochem Mol Biol. 2010 Oct;45(5):351-423
pubmed: 20812779
J Autoimmun. 2011 May;36(3-4):239-52
pubmed: 21376533
Dermatol Online J. 2011 Oct 15;17(10):3
pubmed: 22031629
N Engl J Med. 2011 Dec 1;365(22):2110-21
pubmed: 22129255
Arthritis Rheum. 1990 Oct;33(10):1582-5
pubmed: 2222540
Nat Methods. 2013 Mar;10(3):211-20
pubmed: 23443633
Crit Rev Biochem Mol Biol. 2013 May-Jun;48(3):222-72
pubmed: 23547785
Blood. 2013 Dec 12;122(25):4054-67
pubmed: 24174628
J Clin Cell Immunol. 2013 Apr;4:null
pubmed: 24244889
Int J Nanomedicine. 2013;8:4745-56
pubmed: 24379662
Immunity. 2014 Jul 17;41(1):14-20
pubmed: 25035950
Autoimmun Rev. 2015 Jan;14(1):75-9
pubmed: 25449682
Int J Clin Exp Med. 2014 Dec 15;7(12):4975-82
pubmed: 25663995
Immunology. 1985 May;55(1):31-4
pubmed: 2581888
Clin Exp Immunol. 2015 Sep;181(3):417-26
pubmed: 25959453
Matrix Biol. 2016 Jan;49:37-60
pubmed: 26407638
Clin Immunol. 2017 Dec;185:59-73
pubmed: 27519955
Sci Rep. 2016 Sep 13;6:32659
pubmed: 27619752
Arthritis Rheum. 1988 Apr;31(4):457-64
pubmed: 3258749
Clin Exp Immunol. 1988 Apr;72(1):55-9
pubmed: 3396221
J Clin Invest. 1970 Jul;49(7):1374-80
pubmed: 4194190
Clin Exp Immunol. 1983 Sep;53(3):541-6
pubmed: 6604604
Clin Exp Immunol. 1994 Apr;96(1):20-5
pubmed: 7512007
Biochem Biophys Res Commun. 1993 May 14;192(3):1175-81
pubmed: 7685161
Lupus. 1994 Dec;3(6):455-9
pubmed: 7704001
Inflamm Res. 1995 Dec;44(12):529-34
pubmed: 8788233
Rinsho Ketsueki. 1998 Jun;39(6):436-41
pubmed: 9695672
Proc Natl Acad Sci U S A. 1998 Oct 27;95(22):13313-8
pubmed: 9789085

Auteurs

Estefania Ugarte-Berzal (E)

Laboratory of Immunobiology, Rega Institute for Medical Research, KU Leuven, Leuven, Belgium.

Lise Boon (L)

Laboratory of Immunobiology, Rega Institute for Medical Research, KU Leuven, Leuven, Belgium.

Erik Martens (E)

Laboratory of Immunobiology, Rega Institute for Medical Research, KU Leuven, Leuven, Belgium.

Vasily Rybakin (V)

Laboratory of Immunobiology, Rega Institute for Medical Research, KU Leuven, Leuven, Belgium.

Daniel Blockmans (D)

Department of General Internal Medicine, University Hospital Gasthuisberg, KU Leuven, Leuven, Belgium.

Jennifer Vandooren (J)

Laboratory of Immunobiology, Rega Institute for Medical Research, KU Leuven, Leuven, Belgium.

Paul Proost (P)

Laboratory of Molecular Immunology, Rega Institute for Medical Research, Department of Microbiology and Immunology, KU Leuven, Leuven, Belgium.

Ghislain Opdenakker (G)

Laboratory of Immunobiology, Rega Institute for Medical Research, KU Leuven, Leuven, Belgium.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH